Cytokinetics (CYTK) – Investment Analysts’ Recent Ratings Updates

Cytokinetics (NASDAQ: CYTK) has recently received a number of price target changes and ratings updates:

• 10/12/2026 – Cytokinetics was upgraded by Wall Street Zen from “sell” to “hold”.
• 10/8/2026 – Cytokinetics had its price target raised by Royal Bank Of Canada from $112.00 to $113.00. They now have an “outperform” rating on the stock.
• 10/4/2026 – Cytokinetics was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/26/2026 – Cytokinetics was upgraded by Wall Street Zen from “sell” to “hold”.
• 9/11/2026 – Cytokinetics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 9/1/2026 – Cytokinetics was upgraded by Morgan Stanley from “overweight” to “buy”.
• 8/31/2026 – Cytokinetics had its “buy” rating reaffirmed by HC Wainwright. They now have a $140.00 price target on the stock.
• 8/29/2026 – Cytokinetics was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/16/2026 – Cytokinetics was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/14/2026 – Cytokinetics had its “buy” rating reaffirmed by HC Wainwright.
• 8/13/2026 – Cytokinetics had its price target raised by Barclays PLC from $95.00 to $110.00. They now have an “overweight” rating on the stock.
• 8/13/2026 – Cytokinetics had its price target raised by JPMorgan Chase & Co. from $97.00 to $103.00. They now have an “overweight” rating on the stock.

Insider Activity at Cytokinetics

In related news, Director B. Parshall sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $71.48, for a total transaction of $357,400.00. Following the sale, the director owned 10,784 shares of the company’s stock, valued at $770,840.32. The trade was a 31.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert E. Landry sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $72.13, for a total value of $72,130.00. Following the completion of the sale, the director owned 8,184 shares of the company’s stock, valued at $590,311.92. This trade represents a 10.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 183,926 shares of company stock valued at $13,130,285. 2.60% of the stock is currently owned by insiders.

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that improve muscle function. The company applies muscle biology and molecular pharmacology to develop therapies for cardiovascular and neuromuscular diseases in which impaired muscle performance contributes to disease progression or disability.

Its lead programs include aficamten, a next-generation cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy, and other investigational compounds designed to modulate the activity of cardiac or skeletal muscle.